ORIGINAL RESEARCH
Accepted on 16 Oct 2025
Relapsed or Refractory Central Nervous System Lymphoma Successfully Treated by Glofitamab Combined with Lenalidomide
- 142 views
- Frontiers in Hematology
- Blood Cancer
- Research Topics
- New molecular targets for personalized treatment for Low-Grade Non-Hodgkin Lymphoma
New molecular targets for personalized treatment for Low-Grade Non-Hodgkin Lymphoma
1,126
Total downloads
6,707
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
REVIEW
Published on 16 Jul 2025
The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
doi 10.3389/frhem.2025.1624046
- 1,269 views
ORIGINAL RESEARCH
Published on 16 Apr 2025
Dual targeting of EZH2 and PD-L1 in Burkitt’s lymphoma enhances immune activation and induces apoptotic pathway
doi 10.3389/fimmu.2025.1578665
- 3,028 views
- 1 citation
Published in
Frontiers in Hematology
Blood Cancer
Participating Journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: